PRA Health Sciences Launches New Initiative to Bolster Workforce

Food and Healthcare Press Releases Tuesday July 21, 2015 08:20
RALEIGH, N.C.--(GLOBE NEWSWIRE)--July 20, 2015

PRA Health Sciences (PRA) (NASDAQ:PRAH) is looking to hire new talent. To help attract potential employees from around the world, PRA, a leading global contract research organization (CRO), is launching a new Candidate Experience initiative. Just as PRA is finding innovative ways to improve the clinical development process, it is also developing creative strategies to meet the ever-growing need to identify highly skilled clinical research employees.

"The CRO industry requires many unique skill sets and finding the right talent can be a challenge," said PRA Vice President of Talent Acquisition Glenn Sward. "PRA's new Candidate Experience initiative is designed to attract the highest caliber talent and give potential employees a comprehensive view of our culture and the many rewards of working in an industry that helps bring life-saving drugs to market."

The Candidate Experience includes a new website (www.discoveryourpra.com) which features profiles and videos of a small cross section of current PRA employees. The profiles are designed to give candidates a unique glimpse into clinical development work and why employees find it meaningful. It also includes information about the many benefits of working for PRA.

The Candidate Experience complements several other PRA initiatives, including its highly successful Bridge Program which addresses the pressing need to recruit qualified clinical research associates (CRAs). "The tremendous growth of our industry is driving the demand for more CRAs," said Sward. "PRA's Bridge Program is an innovative training program that transitions qualified RNs, study coordinators, and allied health professionals to a CRA role."

PRA's Oncology University was also developed to respond to the industry need for oncology-experienced CRAs. The program trains experienced CRAs, giving them the knowledge and skills to handle the specific demands of oncology clinical studies. In addition, the PRA Program was created to give recent college graduates a hands-on view of career opportunities within PRA, and to identify promising candidates and streamline them into clinical studies.

The PRA Candidate Experience helps candidates learn more about PRA's people and culture. It is another step in helping to identify talented individuals who may become part of PRA's future workforce - a workforce that is dedicated to advancing drug discovery and improving patients' lives.

ABOUT PRA HEALTH SCIENCES

At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions(TM) model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.

CONTACT: INQUIRIES:
Christine Rogers, Manager - Public Relations,
Corporate Communications
EMAIL: rogerschristine@prahs.com
PHONE: +1 919.786.8463
Global Headquarters
4130 ParkLake Avenue,
Suite 400
Raleigh, North Carolina USA
PHONE: +1 919.786.8200
www.prahs.com

Latest Press Release

Accor Pattaya Blood Donation #3/2019

On Tuesday 17th, September 2019, Hotel Baraquda Pattaya - MGallery and Mercure Pattaya Hotel attended to Accor Pattaya Blood Donation #3/2019 at Veranda Resort Pattaya Na Jomtien - MGallery, MM Meeting Room. The event started at 10.00 a.m. to 02.00 p.m....

Tresiba(R) Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

According to new data from the CONCLUDE head-to-head trial, Tresiba(R) (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in...

BookDoc, partners it#s way to being Southeast Asia#s Next Generation Healthcare Ecosystem is looking to raise Series A from Strategic partners

This year crosses 100 strategic partnerships in over 20 cities across Malaysia, Singapore, Indonesia, Thailand and Hong Kong. Since commenced operations in 2015, BookDoc has grown exponentially with four consecutive years of over 450% annual growth rate...

United Nations Political Declaration on Universal Health Coverage Finally has Some Teeth

FDI World Dental Federation (FDI) welcomes the long overdue commitment to strengthening oral health in the UN Political Declaration on Universal Health Coverage (UHC). The declaration will be officially adopted by world leaders at the UN High-Level...

Ozempic(R) Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza(R) and Canagliflozin in People With Type 2 Diabetes

Novo Nordisk announced today the results from two Ozempic(R) (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic(R) was superior to treatment with the SGLT-2 inhibitor canagliflozin...

Related Topics